Comparative Pharmacology
Head-to-head clinical analysis: APRISO versus CANASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRISO versus CANASA.
APRISO vs CANASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene synthesis, scavenging free radicals, and activating peroxisome proliferator-activated receptor-gamma (PPAR-γ).
Mesalamine (5-aminosalicylic acid) is an anti-inflammatory agent that inhibits prostaglandin and leukotriene synthesis, scavenges reactive oxygen species, and inhibits cytokine production and nuclear factor-kappa B (NF-κB) activation in colonic mucosa.
1.5 g (3 capsules) orally once daily in the morning. Each capsule contains 0.5 g mesalamine.
Mesalamine 1000 mg rectally once daily at bedtime, or 500 mg rectally twice daily (morning and evening). Administered as suppository for ulcerative colitis.
None Documented
None Documented
8.6 ± 4.2 hours for mesalamine; after multiple dosing, effective half-life ~12 hours. Clinical context: allows twice-daily dosing.
Terminal elimination half-life of mesalamine is approximately 0.5-2 hours; however, the N-acetyl metabolite has a half-life of 5-10 hours. Due to the sustained-release formulation, clinical effects persist beyond the plasma half-life.
Renal (primarily as acetylated metabolite, ~80%) and fecal (~20%).
Renal (approximately 20-30% as unchanged drug and metabolites, primarily N-acetyl-5-aminosalicylic acid); biliary/fecal (the remainder, with extensive enterohepatic circulation).
Category C
Category C
Aminosalicylate
Aminosalicylate